Eptinezumab demonstrated efficacy regardless of prior preventive migraine treatment failure: Post hoc DELIVER analyses

被引：0
|
作者：
Pozo-Rosich, Patricia [1 ,2 ]
Ashina, Messoud [3 ,4 ]
Tepper, Stewart J. [5 ]
Jensen, Sidsel [6 ]
Boserup, Line Pickering [6 ]
Josiassen, Mette Krog [6 ]
Sperling, Bjorn [6 ]
机构：
[1] Vall Hebron Univ Hosp & Res Inst, Headache Unit & Res Grp, Barcelona, Spain
[2] Univ Autonoma Barcelona, Barcelona, Spain
[3] Copenhagen Univ Hosp, Rigshosp, Danish Headache Ctr, Dept Neurol, Copenhagen, Denmark
[4] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[5] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[6] Lundbeck AS, Copenhagen, Denmark
来源：
CEPHALALGIA | 2023年 / 43卷 / 1supp期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IHC23-PO-2
引用
收藏
页码：227 / 227
页数：1
相关论文
共 50 条
  • [41] Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses
    Lebwohl, Mark G.
    Armstrong, April W.
    Alexis, Andrew F.
    Lain, Edward L.
    Jacobson, Abby A.
    DERMATOLOGY AND THERAPY, 2024, 14 (10) : 2709 - 2726
  • [42] Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure
    Ruff, Dustin D.
    Ford, Janet H.
    Tockhorn-Heidenreich, Antje
    Sexson, Matthew
    Govindan, Sriram
    Pearlman, Eric M.
    Wang, Shuu-Jiun
    Khan, Arif
    Aurora, Sheena K.
    CEPHALALGIA, 2019, 39 (08) : 931 - 944
  • [43] A Phase 3 Study to Evaluate Eptinezumab for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-2) Trial
    Lipton, R. B.
    Saper, J.
    Ashina, M.
    Biondi, D.
    Bhattacharya, S.
    Hirman, J.
    Schaeffler, B.
    Cady, R.
    HEADACHE, 2018, 58 : 80 - 80
  • [44] Consistent Efficacy Demonstrated By Avatrombopag in Immune Thrombocytopenia (ITP) Regardless of the Number of Lines of Prior ITP Treatment
    Blinder, Morey
    Vredenburg, Michael
    Tian, Wei
    Jamieson, Brian
    McCrae, Keith R.
    BLOOD, 2020, 136
  • [45] Eptinezumab Demonstrated Migraine Preventive Efficacy on Day 1 After Dosing: Closed Testing Analysis From PROMISE-1 and PROMISE-2
    Dodick, D. W.
    Gottschalk, C. H.
    Tepper, S. J.
    Friedman, D., I
    Cady, R.
    Smith, J.
    Hirman, J.
    Snapinn, S.
    HEADACHE, 2020, 60 : 94 - 95
  • [46] Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial
    Pozo-Rosich, P.
    Nagy, K.
    Tassorelli, C.
    Lanteri-Minet, M.
    Sacco, S.
    Nezadal, T.
    Finnegan, M.
    Guo, H.
    Ferreira, De Abreu R.
    Trugman, J.
    HEADACHE, 2023, 63 : 117 - 117
  • [47] Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial
    Pozo-Rosich, Patricia
    Nagy, Krisztian
    Tassorelli, Cristina
    Lanteri-Minet, Michel
    Sacco, Sara
    Nezadal, Tomas
    Finnegan, Michelle
    Guo, Hua
    Ferreira, Rosa De Abreu
    Trugman, Joel M.
    CEPHALALGIA, 2023, 43 (1supp) : 47 - 49
  • [48] Eptinezumab Demonstrated Migraine Preventive Efficacy on Day 1 After Dosing: Closed Testing Analysis from PROMISE-1 and PROMISE-2
    Dodick, David W.
    Gottschalk, Christopher
    Tepper, Stewart J.
    Friedman, Deborah I.
    Cady, Roger
    Smith, Jeff
    Hirman, Joe
    Snapinn, Steve
    NEUROLOGY, 2020, 94 (15)
  • [49] Sustained and Subsequent Response to Atogepant Among Individuals With Episodic Migraine With Prior Treatment Failure: Post Hoc Analysis of the ELEVATE Trial
    Sacco, Simona
    Nagy, Krisztian
    Chalermpalanupap, Natty
    Vernieri, Fabrizio
    Smith, Jonathan H.
    Holle-Lee, Dagny
    Liu, Yingyi
    Carr, Karen
    Pozo-Rosich, Patricia
    Lipton, Richard B.
    CEPHALALGIA, 2023, 43 (1supp) : 265 - 266
  • [50] Measuring dose-related efficacy of eptinezumab for migraine prevention: Post hoc analysis of PROMISE-1 and PROMISE-2
    Apelian, R. G.
    Boyle, L.
    Hirman, J.
    Asher, D.
    HEADACHE, 2022, 62 : 151 - 152
12345